Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scand J Gastroenterol. 2020 Jul; 55(7):800-805.